Company intelligence / Profile preview

Xuanjie Stem Cell Biotechnology

Taiwan

Ownership: Private
Development stage: Other

Overview

Xuanjie has received approval from the Ministry of Health and Welfare for Phase 2 clinical trials for their allogeneic umbilical cord mesenchymal stem cell therapy (UMC119-06-05), targeting chronic obstructive pulmonary disease. Clinical programs in frailty syndrome and knee osteoarthritis are earlier stage.

Therapeutic areas: PulmonologyOtherRheumatology
Modalities: Stem cell therapy
Industry: Biotech

Beyond the preview

Go deeper on Xuanjie Stem Cell Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xuanjie Stem Cell Biotechnology.

Explore the full profile